Operating profit before deduction of amortization: TC BioPharm (TCBP)

TC Biopharm minimizes capital expenditures by outsourcing drug production and testing to external contractors. The GURU.Markets interface reflects the absolute EBITDA trend, where the current status is . Meanwhile, the company aims to localize the final processing of samples to reduce its reliance on CROs. However, the lack of a client base and venture capital volatility make the success of the cancer therapy ecosystem dependent on FDA verdicts.

The specifics of TC Biopharm (TCBP), which depend on venture capital infusions and early-stage development risks, make monitoring the business's ability to independently generate value critically important. By analyzing EBITDA_Co dynamics, an investor assesses the actual cash flow from core operations excluding depreciation and taxes, which allows for the determination of the company's degree of financial autonomy and the risk of stagnation in its market capitalization.